Discovery of Substituted 1,2,3-Triazolyl-Benzoylacetamides as Potent MMP-9 Inhibitors with Anti-Angiogenic Activity in MDA-MB-231 TripleNegative Breast Cancer

Matrix metalloproteinase-9 (MMP-9) contributes to extracellular matrix remodeling, tumor invasion, and angiogenesis, making it an attractive therapeutic target for triple-negative breast cancer (TNBC). The present study aimed to develop non-hydroxamate MMP-9 inhibitors based on a substituted 1,2,3-triazolyl-benzoylacetamide scaffold and evaluate their antiproliferative and anti-angiogenic potentials. An energy-based, structure-guided pharmacophore approach was employed to define the key recognition features of the MMP-9 catalytic domain, including the catalytic Zn²⁺ environment and S1′ specificity pocket. A focused series of 13 derivatives (8a–8m) was subsequently designed through systematic modification of the benzoyl R¹ and terminal phenoxy R² regions, synthesized through a multistep route, and structurally characterized using spectroscopic and mass-spectrometric methods. The synthesized compounds exhibited concentrationdependent MMP-9 inhibition and antiproliferative activity against MDA-MB-231 cells, with the SAR analysis demonstrating a strong dependence on the combined steric, electronic, and lipophilic characteristics of R¹ and R². Compound 8h emerged as the principal lead, whereas 8e and 8l also displayed favorable biochemical and cellular activity profiles. Morphological evaluation further supported the cellular effects of these active derivatives. Functional antiangiogenic assessment demonstrated that 8h concentration-dependently suppressed VEGF-induced HUVEC migration and disrupted capillary-like tube formation, approaching the activity of the reference anti-angiogenic agent at higher tested concentrations. Collectively, these findings identify substituted 1,2,3-triazolyl-benzoylacetamides as a promising nonhydroxamate chemotype for MMP-9-directed anti-angiogenic drug discovery and establish 8h as a lead candidate for further mechanistic, selectivity, pharmacokinetic, and in vivo evaluations.

Authors

Institutions

Publication Details

Journal
International Journal of Drug Delivery Technology
Published
2026-11-16
DOI
https://doi.org/10.25258/ijddt.16.80s.45
Primary Topic
Protease and Inhibitor Mechanisms
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Discovery of Substituted 1,2,3-Triazolyl-Benzoylacetamides as Potent MMP-9 Inhibitors with Anti-Angiogenic Activity in MDA-MB-231 TripleNegative Breast Cancer

Shaik Khasimbi, Sharad Wakode
1 links
International Journal of Drug Delivery Technology
Protease and Inhibitor Mechanisms
article

Discovery of Substituted 1,2,3-Triazolyl-Benzoylacetamides as Potent MMP-9 Inhibitors with Anti-Angiogenic Activity in MDA-MB-231 TripleNegative Breast Cancer

Shaik Khasimbi, Sharad Wakode
article en

Abstract

Matrix metalloproteinase-9 (MMP-9) contributes to extracellular matrix remodeling, tumor invasion, and angiogenesis, making it an attractive therapeutic target for triple-negative breast cancer (TNBC). The present study aimed to develop non-hydroxamate MMP-9 inhibitors based on a substituted 1,2,3-triazolyl-benzoylacetamide scaffold and evaluate their antiproliferative and anti-angiogenic potentials. An energy-based, structure-guided pharmacophore approach was employed to define the key recognition features of the MMP-9 catalytic domain, including the catalytic Zn²⁺ environment and S1′ specificity pocket. A focused series of 13 derivatives (8a–8m) was subsequently designed through systematic modification of the benzoyl R¹ and terminal phenoxy R² regions, synthesized through a multistep route, and structurally characterized using spectroscopic and mass-spectrometric methods. The synthesized compounds exhibited concentrationdependent MMP-9 inhibition and antiproliferative activity against MDA-MB-231 cells, with the SAR analysis demonstrating a strong dependence on the combined steric, electronic, and lipophilic characteristics of R¹ and R². Compound 8h emerged as the principal lead, whereas 8e and 8l also displayed favorable biochemical and cellular activity profiles. Morphological evaluation further supported the cellular effects of these active derivatives. Functional antiangiogenic assessment demonstrated that 8h concentration-dependently suppressed VEGF-induced HUVEC migration and disrupted capillary-like tube formation, approaching the activity of the reference anti-angiogenic agent at higher tested concentrations. Collectively, these findings identify substituted 1,2,3-triazolyl-benzoylacetamides as a promising nonhydroxamate chemotype for MMP-9-directed anti-angiogenic drug discovery and establish 8h as a lead candidate for further mechanistic, selectivity, pharmacokinetic, and in vivo evaluations.

International Journal of Drug Delivery TechnologyVol. 16(80s)
Delhi Pharmaceutical Science and Research University (IN)
Good health and well-being
Protease and Inhibitor Mechanisms
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon